Nothing Special   »   [go: up one dir, main page]

HK1220466A1 - 愛帕琳融合蛋白和其用途 - Google Patents

愛帕琳融合蛋白和其用途

Info

Publication number
HK1220466A1
HK1220466A1 HK16108446.5A HK16108446A HK1220466A1 HK 1220466 A1 HK1220466 A1 HK 1220466A1 HK 16108446 A HK16108446 A HK 16108446A HK 1220466 A1 HK1220466 A1 HK 1220466A1
Authority
HK
Hong Kong
Prior art keywords
fusion proteins
apelin fusion
apelin
proteins
fusion
Prior art date
Application number
HK16108446.5A
Other languages
English (en)
Inventor
Panayiotis Stevis
Jesper Gromada
Andrew Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HK1220466A1 publication Critical patent/HK1220466A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
HK16108446.5A 2013-03-14 2016-07-18 愛帕琳融合蛋白和其用途 HK1220466A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786172P 2013-03-14 2013-03-14
US201361906567P 2013-11-20 2013-11-20
PCT/US2014/028384 WO2014152955A1 (en) 2013-03-14 2014-03-14 Apelin fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
HK1220466A1 true HK1220466A1 (zh) 2017-05-05

Family

ID=50680161

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108446.5A HK1220466A1 (zh) 2013-03-14 2016-07-18 愛帕琳融合蛋白和其用途

Country Status (16)

Country Link
US (3) US9353163B2 (zh)
EP (1) EP2970415B1 (zh)
JP (1) JP6525951B2 (zh)
KR (1) KR20150127596A (zh)
CN (1) CN105026423A (zh)
AU (1) AU2014236451B2 (zh)
BR (1) BR112015020587A2 (zh)
CA (1) CA2904731A1 (zh)
EA (1) EA201591700A1 (zh)
ES (1) ES2708957T3 (zh)
HK (1) HK1220466A1 (zh)
IL (1) IL240587A0 (zh)
MX (1) MX365551B (zh)
SG (1) SG11201506335YA (zh)
WO (1) WO2014152955A1 (zh)
ZA (1) ZA201505927B (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201591700A1 (ru) 2013-03-14 2015-12-30 Ридженерон Фармасьютикалз, Инк. Гибридные белки апелина и их применение
KR20160031552A (ko) 2013-07-25 2016-03-22 노파르티스 아게 합성 아펠린 폴리펩티드의 생체접합체
PE20160878A1 (es) 2013-07-25 2016-09-08 Novartis Ag Polipeptidos ciclicos para el tratamiento de la insuficiencia cardiaca
US10155811B2 (en) 2013-11-20 2018-12-18 Regeneron Pharmaceuticals, Inc. APLNR modulators and uses thereof
GB201407532D0 (en) * 2014-04-29 2014-06-11 Univ Ulster Apelin analogues
MX370689B (es) 2014-06-10 2019-12-19 Amgen Inc Polipeptidos apelina.
WO2016061141A1 (en) * 2014-10-13 2016-04-21 University Of Maryland, Baltimore Methods for treating cardiovascular dysfunction and improving fluid homeostasis with a peptide hormone
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US20170355734A1 (en) * 2014-12-23 2017-12-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Metabolically Stable Apelin Analogs in the Treatment of Disease Mediated by the Apelin Receptor
EP3240561A4 (en) * 2014-12-29 2018-07-11 Academia Sinica Method for treating influenza a virus infection
BR112017014194A2 (pt) 2015-01-23 2018-01-09 Novartis Ag conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada
AR105616A1 (es) * 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
US11542321B2 (en) 2017-03-22 2023-01-03 Research Corporation Technologies, Inc. Engineered stable CH2 polypeptides
US11578112B2 (en) * 2017-03-29 2023-02-14 University Of Miyazaki Long-acting adrenomedullin derivative conjugated with Fc region of immunoglobulin
JP7161494B2 (ja) * 2017-05-06 2022-10-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Aplnrアンタゴニストおよびvegf阻害剤によって眼疾患を治療する方法
CN109771634A (zh) * 2017-07-11 2019-05-21 南华大学 含有apelin 12环肽的药物组合物及用途
CA3072261A1 (en) * 2017-08-24 2019-02-28 Phanes Therapeutics, Inc. Anti-apelin antibodies and uses thereof
GB201805675D0 (en) * 2018-04-05 2018-05-23 Davenport Anthony Peter Compounds For Use As Apelin Receptor Antagonists
CN110655577A (zh) * 2018-06-13 2020-01-07 鸿运华宁(杭州)生物医药有限公司 APJ抗体及其与Elabela的融合蛋白质,以及其药物组合物和应用
US20230242672A1 (en) * 2020-06-25 2023-08-03 Gliknik Inc. Ace2-fc fusion proteins and methods of use
CN112546198B (zh) * 2020-12-17 2022-03-25 温州医科大学慈溪生物医药研究院 一种用于治疗脑中风和急性脑梗的药物组合物
CN113648418B (zh) * 2021-05-08 2022-08-05 南方医科大学 Apelin-APJ抑制剂在制备治疗血睾屏障损伤药物中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2065299C (en) 1989-08-09 2001-07-24 Buck A. Rhodes Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
WO1999033976A1 (en) 1997-12-24 1999-07-08 Takeda Chemical Industries, Ltd. Polypeptide, their production and use
US6475718B2 (en) 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
CA2391080A1 (en) * 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
AU2001296023A1 (en) * 2000-10-30 2002-05-15 Takeda Chemical Industries Ltd. Process for producing peptide
ATE325865T1 (de) 2001-01-16 2006-06-15 Regeneron Pharma Isolierung von sezernierte proteine exprimierenden zellen
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
DE10138569A1 (de) 2001-08-06 2003-04-30 Bayer Ag Regulation des APJ-Rezeptors
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
WO2004081198A2 (en) 2003-03-12 2004-09-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis with apelin compositions
US7450586B2 (en) * 2003-07-22 2008-11-11 Motorola, Inc. Network header compression arrangement
EP1711610A2 (en) * 2004-01-28 2006-10-18 Syntonix Pharmaceuticals, Inc. HETERODIMERIC FOLLICLE STIMULATING HORMONE-Fc (FSH-Fc) FUSION PROTEINS FOR THE TREATMENT OF INFERTILITY
WO2005106493A1 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj)
US20060045880A1 (en) 2004-08-23 2006-03-02 Krieg Paul A Methods for modulating angiogenesis and apoptosis with apelin compositions
US20060159676A1 (en) 2005-01-14 2006-07-20 Krieg Paul A Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
US8673848B2 (en) * 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
CA2634363A1 (en) 2005-12-20 2007-06-28 Takeda Pharmaceutical Company Limited Novel application of apelin
CN105131127B (zh) * 2007-05-30 2018-09-07 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
DK2150617T3 (en) 2007-06-04 2015-01-12 Regeneron Pharma Regions with increased expression and stability
EP2362878A4 (en) 2008-11-04 2015-09-16 Anchor Therapeutics Inc APJ RECEPTOR COMPOUNDS
JP2012518398A (ja) * 2009-02-24 2012-08-16 グラクソ グループ リミテッド 抗原結合性構築物
US8946382B2 (en) 2009-02-27 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apelin peptides and methods of use
US9174428B2 (en) * 2009-08-10 2015-11-03 Corning Incorporated Roll mechanics for enabling printed electronics
KR20240007725A (ko) 2009-11-02 2024-01-16 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 치료학적 뉴클레아제 조성물 및 방법
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
AU2011283694B2 (en) * 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points
US8881594B2 (en) * 2011-03-06 2014-11-11 Alexander Henry Slocum Tapered spiral bellows pressure sensor
EP3045183B1 (en) * 2011-03-11 2018-07-04 Genzyme Corporation Pegylated apelin and uses thereof
EP2692352A4 (en) 2011-03-31 2014-12-24 Shiseido Co Ltd MEANS FOR SUPPRESSING HEADWALLS
EP2734546A1 (en) 2011-07-18 2014-05-28 Amgen Inc. Apelin antigen-binding proteins and uses thereof
US9863605B2 (en) * 2011-11-23 2018-01-09 Quarkstar Llc Light-emitting devices providing asymmetrical propagation of light
CN102516393B (zh) 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
CN102675470B (zh) * 2012-04-01 2015-06-17 江苏省弗泰生物科技有限公司 SCF-Fc融合蛋白
US20160067347A1 (en) 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
EA201591700A1 (ru) 2013-03-14 2015-12-30 Ридженерон Фармасьютикалз, Инк. Гибридные белки апелина и их применение
US10155811B2 (en) 2013-11-20 2018-12-18 Regeneron Pharmaceuticals, Inc. APLNR modulators and uses thereof

Also Published As

Publication number Publication date
MX2015011350A (es) 2016-01-15
US20160237130A1 (en) 2016-08-18
US9353163B2 (en) 2016-05-31
US20140275489A1 (en) 2014-09-18
JP2016513733A (ja) 2016-05-16
WO2014152955A1 (en) 2014-09-25
EA201591700A1 (ru) 2015-12-30
SG11201506335YA (en) 2015-09-29
AU2014236451A1 (en) 2015-10-15
KR20150127596A (ko) 2015-11-17
ES2708957T3 (es) 2019-04-12
EP2970415B1 (en) 2018-12-19
US20180030099A1 (en) 2018-02-01
IL240587A0 (en) 2015-09-24
BR112015020587A2 (pt) 2017-10-10
CN105026423A (zh) 2015-11-04
US9751921B2 (en) 2017-09-05
EP2970415A1 (en) 2016-01-20
ZA201505927B (en) 2017-03-29
JP6525951B2 (ja) 2019-06-05
CA2904731A1 (en) 2014-09-25
MX365551B (es) 2019-06-07
AU2014236451B2 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
IL276106A (en) Garp-binding proteins and their uses
HK1220466A1 (zh) 愛帕琳融合蛋白和其用途
IL261743B (en) and their uses 33–il antibodies against
IL240034A0 (en) Chimeric proteins based on l1–pd and –pd–l2 and their uses
IL261547B (en) Antibodies against pesidine and their uses
EP2968551A4 (en) FUSION PROTEINS AND METHOD THEREFOR
IL245040A0 (en) Antibodies against pdgfr-beta and their uses
IL243974A0 (en) Antibodies against -prlr and uses
SG10201708143QA (en) Anti-c10orf54 antibodies and uses thereof
SG11201509116VA (en) Anti-tweakr antibodies and uses thereof
PL2983704T4 (pl) Polipeptydy i szczepionki fuzyjne
HK1220903A1 (zh) 軟骨結合型融合蛋白
EP2930189A4 (en) CHEMOKINE-CYTOKINE FUSION PROTEIN AND USE THEREOF
EP3029071A4 (en) Saxatilin-fc fusion protein and use thereof
AU2013901331A0 (en) Fusion Proteins and Use Thereof